A detailed history of Northern Trust Corp transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Northern Trust Corp holds 742,904 shares of IONS stock, worth $27 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
742,904
Previous 717,975 3.47%
Holding current value
$27 Million
Previous $34.2 Million 13.03%
% of portfolio
0.0%
Previous 0.01%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$40.06 - $51.86 $998,655 - $1.29 Million
24,929 Added 3.47%
742,904 $29.8 Million
Q2 2024

Aug 14, 2024

BUY
$36.45 - $47.7 $937,785 - $1.23 Million
25,728 Added 3.72%
717,975 $34.2 Million
Q1 2024

May 14, 2024

BUY
$42.03 - $53.55 $179,089 - $228,176
4,261 Added 0.62%
692,247 $30 Million
Q4 2023

Feb 13, 2024

SELL
$43.39 - $51.63 $118,801 - $141,362
-2,738 Reduced 0.4%
687,986 $34.8 Million
Q3 2023

Nov 13, 2023

BUY
$38.5 - $47.13 $756,371 - $925,915
19,646 Added 2.93%
690,724 $31.3 Million
Q2 2023

Aug 11, 2023

BUY
$34.73 - $43.33 $438,014 - $546,477
12,612 Added 1.92%
671,078 $27.5 Million
Q1 2023

May 15, 2023

BUY
$33.58 - $41.2 $630,531 - $773,612
18,777 Added 2.94%
658,466 $23.5 Million
Q4 2022

Feb 13, 2023

BUY
$37.12 - $46.52 $595,738 - $746,599
16,049 Added 2.57%
639,689 $24.2 Million
Q3 2022

Nov 14, 2022

SELL
$36.54 - $48.66 $66,941 - $89,145
-1,832 Reduced 0.29%
623,640 $27.6 Million
Q2 2022

Aug 12, 2022

SELL
$31.71 - $43.0 $731,296 - $991,666
-23,062 Reduced 3.56%
625,472 $23.2 Million
Q1 2022

May 13, 2022

SELL
$29.88 - $37.04 $369,197 - $457,666
-12,356 Reduced 1.87%
648,534 $24 Million
Q4 2021

Feb 08, 2022

BUY
$25.61 - $35.1 $140,061 - $191,961
5,469 Added 0.83%
660,890 $20.1 Million
Q3 2021

Nov 15, 2021

SELL
$33.54 - $40.55 $541,738 - $654,963
-16,152 Reduced 2.41%
655,421 $22 Million
Q2 2021

Aug 13, 2021

SELL
$34.54 - $47.25 $5.86 Million - $8.01 Million
-169,572 Reduced 20.16%
671,573 $26.8 Million
Q1 2021

May 12, 2021

BUY
$42.51 - $63.78 $678,927 - $1.02 Million
15,971 Added 1.94%
841,145 $37.8 Million
Q4 2020

Feb 11, 2021

SELL
$45.3 - $60.27 $288,198 - $383,437
-6,362 Reduced 0.77%
825,174 $46.7 Million
Q3 2020

Nov 16, 2020

BUY
$47.45 - $62.95 $44,555 - $59,110
939 Added 0.11%
831,536 $39.5 Million
Q2 2020

Aug 14, 2020

SELL
$46.85 - $61.05 $229,377 - $298,900
-4,896 Reduced 0.59%
830,597 $49 Million
Q1 2020

May 14, 2020

BUY
$41.6 - $63.4 $1.55 Million - $2.36 Million
37,206 Added 4.66%
835,493 $39.5 Million
Q4 2019

Feb 14, 2020

SELL
$53.85 - $65.27 $52,288 - $63,377
-971 Reduced 0.12%
798,287 $48.2 Million
Q3 2019

Nov 13, 2019

SELL
$59.06 - $72.15 $392,099 - $479,003
-6,639 Reduced 0.82%
799,258 $47.9 Million
Q2 2019

Aug 13, 2019

BUY
$62.09 - $86.14 $9.52 Million - $13.2 Million
153,326 Added 23.5%
805,897 $51.8 Million
Q1 2019

May 13, 2019

BUY
$52.92 - $81.17 $305,930 - $469,243
5,781 Added 0.89%
652,571 $53 Million
Q4 2018

Feb 12, 2019

BUY
$43.37 - $59.54 $285,287 - $391,654
6,578 Added 1.03%
646,790 $35 Million
Q3 2018

Nov 14, 2018

BUY
$42.88 - $53.7 $796,238 - $997,155
18,569 Added 2.99%
640,212 $33 Million
Q2 2018

Sep 18, 2018

SELL
$40.53 - $50.7 $330,684 - $413,661
-8,159 Reduced 1.3%
621,643 $25.9 Million
Q2 2018

Aug 14, 2018

BUY
$40.53 - $50.7 $1.19 Million - $1.49 Million
29,445 Added 4.9%
629,802 $26.2 Million
Q1 2018

May 09, 2018

BUY
$44.08 - $55.05 $589,570 - $736,293
13,375 Added 2.28%
600,357 $26.5 Million
Q4 2017

Feb 14, 2018

SELL
$50.3 - $64.39 $221,118 - $283,058
-4,396 Reduced 0.74%
586,982 $29.5 Million
Q3 2017

Nov 13, 2017

BUY
$45.56 - $59.57 $26.9 Million - $35.2 Million
591,378
591,378 $30 Million

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $5.16B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.